Acute myelogenous leukemia (AML) is a heterogeneous group of diseases affecting hematopoietic stem cells. In recent years, several novel molecular abnormalities have been identified in patients with AML, particularly in cases with normal karyotype. Among these, mutations of the nucleophosmin gene (NPM1), first described by Falini et al., 1 have been established by several groups as currently the most common abnormality in AML, Figure 1 (a) LNA-clamp aligned to the NPM1 sequence. (b) Amplification and sequence analysis of a sample with or without LNA. High-resolution fragment analysis was performed as outlined recently 8 using primers NPM1-fw (labeled with 6-FAM) and reverse in the presence or absence of the LNA. PCR conditions were as described recently. In brief, a 25 ml PCR was performed with 0.5 mM primer NPMf (5 0 -GTGTTGCGGTTCCTTAACCA-3 0 ) or NPMf-FAM (5 0 -FAM-GTGTT GCGGTTCCTTAACCA-3 0 ) for Genescan fragment analysis or NPMf-BIO (5 0 -biotin-GTGTTGCGGTTCCTTAACCA-3 0 ) for array detection and 0.25 mM NPM1r (5 0 -AACGGTTCTTACACAACAGG-3 0 ) and
0 ( þ N indicates LNA positions). After activation of AmpliTaq Gold polymerase (0.5 U; Applied Biosystems, Darmstadt, Germany) at 951C for 11 min, followed by a total of 33 cycles with 951C/10 s, 541C/10 s and 601C/10 s. If samples were analyzed by Genescan, a final step with 40 min at 601C was added to the reaction to complete addition of A-overhangs. 8 (c) Direct sequencing of PCRproducts generated in the presence or absence of the LNA-clamp. Sequencing was performed as described recently 8 using the NPM1r-primer on an ABI377XL automated sequencer. (d) Array hybridization and staining was performed according to the manufacturer's instructions. In brief, 12.5 ml of the biotinylated PCR product were combined with 25 ml of the formamide-based hybridization buffer and applied on the array (30 min, 361C). After a washing step, the enzyme conjugate was added (5 min, 201C) and removed by washing. The specifically bound product was visualized by incubation with the enzyme substrate (2 min), leading to the formation of a dark precipitate. Although these signals are clearly visible, high-resolution images were taken, using a transmission-light film scanner (Chipron Letters to the Editor found in about half of all AML patients with normal karyotype.
1,2 On the molecular level, these mutations are characterized by insertion mutations which cluster in an 8 bp region within exon 12 of the NPM1 gene. 3 All mutations reported so far induce a net insertion of 4 bp, leading to frameshift and an elongated protein containing a novel nuclear export signal which induces an increased transport of the NPM1 protein to the cytoplasm. 3 This abnormal localization can be used for mutation screening using protein staining. 1 For the detection of NPM1 mutations on the molecular level, several different assays have been described, including direct sequencing, 1 high-resolution fragment analysis, 4 melting curve analysis and denaturing high-performance liquid chromatography. 5 The information on the presence of an NPM1 mutation seems to have major prognostic relevance. In addition to that, NPM1 mutations might be also suitable as target structure for minimal residual disease (MRD) monitoring. 6 For this, it is important to know the precise type of mutation present in the patient. About 75-80% of all mutations represent a tandem duplication of the four bases TCTG, this mutation has been designated Type A. 1 Another 10-12% of mutations are comprised by Type B (CATG) or Type D (CCTG) mutations, whereas the remaining about 10% of cases carry more than 30 different alterations. 3 Identification of the precise sequence alteration present in a clinical sample might be difficult due to several factors. Owing to the frameshift induced and the overlay of different sequences, the mutated sequence might be difficult to read unambiguously, especially if more complex deletion/insertion mutations are present. In addition, direct sequence analysis typically has a limit of detection of about 20% of a minor allele population. Thus, in a substantial number of cases, cloning and sequencing of several (up to 20) clones might be necessary to identify the mutation, making this procedure time consuming and expensive. Here, we describe a novel procedure based on locked nucleic acid (LNA)-mediated clamping of wild-type (wt) NPM1 sequences to identify NPM1 mutations. LNA is a nucleic acid analogue that contains a 2 0 -O,4 0 -C-methylene bridge in the ribose moiety (reviewed by Vester and Wengel
7
). Owing to this modification, oligonucleotides containing LNA monomer bases differ from conventional molecules in that they are able to adopt an Ahelical conformation, which allows better stacking and higher thermal stability in hybridization to perfectly matched DNA sequences. 7 The clamping procedure described here employs this ability for sequence-specific binding by using a mixed LNA/ DNA molecule complementary to the wt NPM1 sequence (Figure 1a) . Owing to the high thermal stability of the hybrid, this molecule is calculated to strongly inhibit wt NPM1 amplification. In contrast, any mutation present in the complementary sequence of the LNA/DNA clamp interferes with the binding, resulting in the preferential amplification of mutant NPM1. We tested this assumption on 460 samples which had been identified by Genescan analysis to carry a 4-bp insertion mutation in NPM1 exon 12.
8 Using LNA-mediated polymerase chain reaction (PCR) clamping, 31 different mutations could be identified in this cohort (Table 1) . These mutations represent all typical mutations identified so far, that is, either simple 4-bp insertions at position 960 or 964 or more complex deletion insertion mutations ( Table 1) . As shown in Table 1 Alignment of the 31 different NPM1 mutations successfully amplified and sequenced in the presence of the LNA-clamp Letters to the Editor Figure 1 , even in cases with only a minor population of NPM1 mutant alleles present in the sample (approx. 5-10%) (Figure 1b , lower panel), reaction with the LNA very efficiently blocks wt-NPM1 amplification (Figure 1b , upper panel) and allows unambiguous identification of the NPM1 mutation (TCTG) present in the sample in the consecutive direct sequence analysis ( Figure 1c, upper panel) . Amplification without the LNA did not allow the identification of the NPM1 mutation in this case (Figure 1c, lower panel) . We further tested the ability to detect minor populations of mutant cells. LNA-clamped PCR products were generated from 1:100 to 1:1000 dilutions of different mutants in excess of the wt-sequence, and were detected using either Genescan fragment analysis or low-density array detection (Chipron, Berlin, Germany). High-resolution fragment analysis differentiates easily between the wt and the mutant band, making this procedure a simple and rapid assay for detection of MRD. Also, the solid-phase hybridization on the array was able to detect the variant as exemplified for type A and B mutations (Figure 1d) , and thus might further enhance the identification of the mutation. The actual detection level is clearly lower than achievable with other procedures, 6 and thus might be insufficient to perform MRD analysis with high sensitivity, detecting cell populations far below 1/1000 cells. However, the flexibility of the assay makes it especially suitable for rapid assessment of the presence of mutations in follow-up samples. This is of major importance in those cases in which only material after start of treatment is available, or when the precise type of mutation is unknown, because initial diagnosis and MRDassessment were performed in different laboratories. In addition, this assay might help to identify the precise mutation type present in those 20% not having mutation Type A, especially for the design of real-time PCR primers and probe sets for MRD quantification. 6 Taken together, the simple procedure described here enables the rapid assessment of NPM1 mutations with a sensitivity of 1/100 to 1/1000 and avoids the necessity of cloning or other steps to unambiguously identify NPM1 alterations. The assay was able to detect more than 30 different NPM1 mutations, thus seems to work with the vast majority of mutations reported so far. It appears to represent a versatile tool for NPM1 mutation detection and might be combined with other assays like fragment analysis or real-time PCR to improve MRD detection. This is especially relevant in those cases having not one of the typical mutations (Type A, B, D) , where establishing an individual real-time PCR assay might be too time consuming in the clinical situation. 
